[1]吴铁雄,刘旭东,朱沪敏,等.大黄?虫胶囊联合心得安治疗乙肝肝硬化门脉高压症临床观察[J].西部中医药,2023,36(02):102-104.[doi:10.12174/j.issn.2096-9600.2023.02.23]
　WU Tiexiong,LIU Xudong,ZHU Humin,et al.Clinical Observation on Dahuang Zhechong Capsules and Propranolol in the Treatment of Portal Hypertension of Hepatitis B Cirrhosis[J].Western Journal of Traditional Chinese Medicine,2023,36(02):102-104.[doi:10.12174/j.issn.2096-9600.2023.02.23]
点击复制

大黄?虫胶囊联合心得安治疗乙肝肝硬化门脉高压症临床观察
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年02期
页码:
102-104
栏目:
出版日期:
2023-02-15

文章信息/Info

Title:
Clinical Observation on Dahuang Zhechong Capsules and Propranolol in the Treatment of Portal Hypertension of Hepatitis B Cirrhosis
作者:
吴铁雄1, 刘旭东2, 朱沪敏1, 黄露1, 李品桦1
1.广西中医药大学，广西 南宁 530001
2.广西中医药大学附属瑞康医院，广西 南宁 530000
Author(s):
WU Tiexiong1, LIU Xudong2, ZHU Humin1, HUANG Lu1, LI Pinghua1
1.Guangxi University of Chinese Medicine, Nanning 530001, China
2.Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530000, China
关键词:
肝硬化; 门静脉高压; 大黄?虫胶囊; 心得安
Keywords:
cirrhosis; portal hypertension; capsules; propranolol
分类号:
R575.2
DOI:
10.12174/j.issn.2096-9600.2023.02.23
文献标志码:
B
摘要:
目的观察大黄?虫胶囊联合心得安治疗门静脉高压症的临床疗效。 方法选择75例乙肝肝硬化门脉高压症患者，随机分为3组。A组给予心得安口服，B组给予心得安+大黄?虫胶囊口服，C组给予心得安+扶正化瘀胶囊口服，疗程6个月。观察3组治疗前后肝功能、脾脏大小、门静脉及脾静脉内径，肝脏硬度、脂肪衰减等指标变化情况。 结果治疗后，各组谷丙转氨酶、谷草转氨酶水平均较治疗前降低（P＜0.05），但治疗后各组间比较，差异无统计学意义（P＞0.05）。治疗后，与A组比较，B组及C组肝硬度值及脂肪衰减值均降低（P＜0.05）；治疗后B组与C组比较，肝硬度值及脂肪衰减值差异无统计学意义（P＞0.05）。治疗后，与A组比较，B组门静脉内径、脾脏厚度与长度均降低（P＜0.05）；与C组比较，B组脾脏长度缩小（P＜0.05）。各组间治疗前后脾静脉内径比较，差异无统计学意义（P＞0.05）。 结论心得安联合大黄蛰虫胶囊治疗乙肝肝硬化门脉高压患者，具有较为显著的临床疗效，可缩小脾脏及门静脉内径，降低肝脏硬度。
Abstract:
ObjectiveTo investigate clinical effects of Dahuang Zhechong capsules joined with propranolol in the treatment of portal hypertension. MethodsAll 75 patients were randomized into three groups, A group took propranolol orally, B group accepted propranolol and Dahuang Zhechong capsules, and C group oral administra-tion of propranolol and Fuzheng Huayu capsules, the course of the treatment was six months. To observe liver function, the size of spleen, inner diameters of portal vein and splenic vein, hepatic hardness, fat attenuation and others in three groups before and after the treatment. ResultsAfter the treatment, the levels of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in different groups were lower than these before the treatment (P<0.05), the difference had no statistical meaning between different groups after the treatment (P>0.05). After the treatment, compared with A group, hepatic hardness and fat attenuation of B and C groups decreased (P<0.05); when B group was compared with C group after the treatment, the difference showed no statistical meaning in hepatic hardness and fat attenuation (P>0.05). After the treatment, inner diameters of portal vein, splenic thickness and length in B group reduced compared with these of A group (P<0.05); compared with C group, splenic length shortened in B group (P<0.05). The difference showed no statistical meaning in inner diameters of splenic vein between different groups before and after the treatment (P>0.05). ConclusionPropranolol and Dahuang Zhechong capsules have the noticeable clinical effects in treating the patients with portal hypertension of hepatitis B cirrhosis, it can shorten the diameter of splenic and portal veins, reduce the hepatic hardness.

相似文献/References:

[1]黄鸿娜,黄晶晶△,王振常,等.柔肝化纤颗粒治疗肝硬化脾功能亢进症的临床观察[J].西部中医药,2014,27(09):111.
[2]张萍,朱建坤.肝硬化患者应用中医食疗的临床护理分析[J].西部中医药,2013,26(07):112.
　ZHANG Ping,ZHU Jiankun.Analysis on Clinical Nursing for Liver Cirrhosis Patients Given with TCM Food Therapy[J].Western Journal of Traditional Chinese Medicine,2013,26(02):112.
[3]刘建军,曾贤翠,郝淑萍,等.腹水超滤浓缩回输联合中医辨证治疗肝硬化顽固性腹水40例临床观察[J].西部中医药,2013,26(06):1.
　LIUJianjun,ZENGXiancui,HAOShuping,et al.ClinicalObservationonUltrafiltrationReinfusionofConcentratedAscitesandSyndromeDifferentiationforRefractoryAscitesofLiverCirrhosis:AReportof40Cases[J].Western Journal of Traditional Chinese Medicine,2013,26(02):1.
[4]樊红,冯彦虎,张德奎△,等.中西医结合治疗肝炎后肝硬化腹水疗效观察[J].西部中医药,2013,26(02):91.
　FAN Hong,FENG Yanhu,ZHANG Dekui,et al.Clinical Observation on Integrative Medicine in Treating Cirrhosis Ascites of Patients with Hepatitis[J].Western Journal of Traditional Chinese Medicine,2013,26(02):91.
[5]闫雪华.恩替卡韦联合复方鳖甲软肝片治疗代偿期乙肝肝硬化疗效观察[J].西部中医药,2014,27(07):84.
　YAN Xuehua.Clinical Observation on Entecavir Combined with Compound BieJia RuanGan Tablets in Treating Decompensated Liver Cirrhosis of Hepatitis B[J].Western Journal of Traditional Chinese Medicine,2014,27(02):84.
[6]龚红霞,邱晶.多层螺旋CT门静脉成像在肝硬化中医证型诊断中的应用价值[J].西部中医药,2018,31(12):147.
　GONG Hongxia,QIU Jing.Application Value of Multilayer Spiral CT Portal Vein Imaging in the Diagnosis of TCM Patterns of Liver Cirrhosis[J].Western Journal of Traditional Chinese Medicine,2018,31(02):147.
[7]朱艳国,朱艳丽△,张金花.自拟化积膏治疗肝硬化疗效观察[J].西部中医药,2019,32(05):63.
　ZHU Yanguo,ZHU Yanli,ZHANG Jinhua.Clinical Observation on Selfmade HuaJi Ointment in Treating Cirrhosis[J].Western Journal of Traditional Chinese Medicine,2019,32(02):63.
[8]陈美岑,等.柔肝化纤颗粒对失代偿期肝硬化患者肠道菌群的影响[J].西部中医药,2021,34(12):99.[doi:10.12174/j.issn.2096-9600.2021.12.26]
　CHEN Meicen,WANG Zhenchang,et al.Effects of Rougan Huaxian Granules on Intestinal Flora in Patients with Decompensated Cirrhosis[J].Western Journal of Traditional Chinese Medicine,2021,34(02):99.[doi:10.12174/j.issn.2096-9600.2021.12.26]
[9]徐婷婷,安振涛,李慧,等.肝硬化腹水证治分布及脐敷疗法用药规律文献研究[J].西部中医药,2021,34(06):85.[doi:10.12174/j.issn.2096-9600.2021.06.20]
　XU Tingting,AN Zhentao,LI Hui,et al.Literature Study on the Distribution of Syndrome Differentiation and Treatment of Cirrhosis Ascites and Medication Rules of Umbilical Compressing Therapy[J].Western Journal of Traditional Chinese Medicine,2021,34(02):85.[doi:10.12174/j.issn.2096-9600.2021.06.20]
[10]马玉珍,毛德文,覃艳新,等.六味醒神颗粒治疗肝硬化轻微型肝性脑病的临床疗效及其对血氨和内毒素的影响[J].西部中医药,2021,34(05):7.[doi:10.12174/j.issn.2096-9600.2021.05.03]
　MA Yuzhen,MAO Dewen,QIN Yanxin,et al.Clinical Effects of Liuwei Xingshen Granules in Treating Mild Hepatic Encephalopathy of Liver Cirrhosis and Its Influence on Blood Ammonia and Endotoxin[J].Western Journal of Traditional Chinese Medicine,2021,34(02):7.[doi:10.12174/j.issn.2096-9600.2021.05.03]

备注/Memo

备注/Memo:
吴铁雄（1993—），男，在读博士研究生，医师。研究方向：肝脏疾病的中西医结合防治。国家自然科学基金（81473532）；2018年广西一流学科建设项目重点课题（2018XK084）；广西中医药适宜技术开发与推广项目（GZSY21-29）；广西中医药大学研究生教育创新计划（YCSY20190077）。
更新日期/Last Update: 2023-02-15